Sickle Cell Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 26 00:02 2023
Sickle Cell Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Sickle Cell Disease Pipeline Insights
DelveInsight’s, “Sickle Cell Disease (SCD) – Pipeline Insights, 2023” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Sickle cell disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

United States, Nevada, Las Vegas, DelveInsight’s Sickle Cell Disease Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Sickle Cell Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Sickle Cell Disease pipeline domain.

Key Takeaways from the Sickle Cell Disease Pipeline Report

  • Over 50+ Sickle Cell Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Sickle Cell Disease market would significantly increase market revenue. 
  • Leading Sickle Cell Disease companies developing novel drug candidates to improve the Sickle Cell Disease treatment landscape include Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals, and others.
  • Promising Sickle Cell Disease pipeline therapies in various stages of development include BPX-501 T cells, Canakinumab, EPI01, CTX001, and others.

Sickle Cell Disease Overview

Sickle cell disease is the name given for a group of inherited conditions that affect the red blood cells and the most serious type is called Sickle cell anemia. Sickle cells are destroyed rapidly in the bodies of people with the disease, causing anemia which is why it is commonly known as sickle cell anemia. The sickle cells also block the flow of blood through vessels, resulting in lung tissue damage that causes acute chest syndrome, pain episodes, stroke, priapism and damage to the spleen, kidneys and liver. Sickle cell disease is a serious and lifelong condition, although long-term treatment can help manage many of the problems associated with it. The disease affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. There is an atypical hemoglobin molecule called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape. Sickle cell disease is caused by a mutation in the hemoglobin-Beta gene found on chromosome.

Sickle Cell Disease Pipeline Analysis: Drug Profile

BPX-501 T cells: Bellicum Pharmaceuticals

BPX-501 T cells (also known as Rivo-cel) is being developed by Bellicum Pharmaceuticals. BPX-501 T cells are derived from non-mobilized donor leukapheresis and are expanded, transduced and selected for the iC9 gene, cryopreserved and shipped back to the clinical site. Currently it is in Phase I/II stage of development for the treatment of Hematological Disorders. Rivo-cel is a T cell therapy incorporating CaspaCIDe safety switch intended to improve HSCT outcomes in the treatment of hematological malignancies and inherited blood disorders. Rivo-cel is designed to treat immunodeficiency following allogeneic HSCT, preventing morbidity and mortality due to disease relapse and infection. 

Discover more about the emerging Sickle Cell Disease drugs @ Sickle Cell Disease Treatment Drugs

Sickle Cell Disease Key Companies

  • Bellicum Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Vertex Pharmaceuticals

Sickle Cell Disease Pipeline Therapies

  • BPX-501 T cells
  • Canakinumab
  • EPI01
  • CTX001

Sickle Cell Disease Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Sickle Cell Disease Pipeline Report 

  • Coverage: Global 
  • Key Sickle Cell Disease Companies: Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals, and others
  • Key Sickle Cell Disease Pipeline Therapies: BPX-501 T cells, Canakinumab, EPI01, CTX001, and others

Find out more about the Sickle Cell Disease treatment options in development @ Sickle Cell Disease Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Sickle Cell Disease pipeline segment.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: